Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 12/2007

01-12-2007 | Short Communication

High-dose corticosteroids for the management of dyspnea in patients with tumor obstruction of the upper airway

Authors: Ahmed Elsayem, Eduardo Bruera

Published in: Supportive Care in Cancer | Issue 12/2007

Login to get access

Excerpt

Dyspnea is a frequent and devastating symptom in patients with advanced cancer [1, 2]. In patients with tumors of the upper mediastinum or neck, dyspnea is accompanied by objective physical findings such as stridor, pain in the area of neck or upper mediastinum, voice changes, and tumor infiltration of the head and neck tissues. This paper describes three cases of subjective and objective improvement of dyspnea because of upper airway involvement with the use of high-dose parenteral corticosteroids. …
Literature
1.
Coweher K, Hanks GW (1990) Long term management of respiratory symptoms in advanced cancer. J Pain Sympt Manag 5:320–330CrossRef
2.
Bruera E, Ripamoni C (1998) Dyspnea in patients with advanced cancer. In: Berger A et al (ed) Principles and practices of supportive oncology, vol. 23. Lippincott–Raven, Philadelphia, pp 295–308
3.
Filippelli M, Pacini F, Romagnoli I et al (2000) Airway obstruction and chronic exertional dyspnea in patients with persistent bronchial asthma. Respir Med 94(7):694–701PubMedCrossRef
4.
Frew AJ, Hogate ST (1993) Clinical pharmacology of asthma. Implications for treatment. Drugs 46:847–862PubMed
5.
Weir Dc, Gove RI, Robertson AS et al (1991) Corticosteroids trials in non-asthmatic chronic airflow obstruction: a comparison of oral prednisolone and inhaled beclomethasone diproprionate. Thorax 45:112–117
6.
Schols Am, Soeters PB, Mostert R et al (1995) Physiologic effects of nutritional support and anabolic steroids in patients in patients with chronic obstructive pulmonary disease: a placebo controlled randomized trial. Am J Respir Crit Care Med 152:1268–1274PubMed
7.
Geimer NF, Donegan WL (1980) Role and mechanism of corticosteroid therapy in breast cancer. Rev Endocr-Relat Cancer 6:5–6
8.
Walsh TD, West TS (1988) Controlling symptoms in advanced cancer. Br Med J 296:477–481CrossRef
9.
Kveton JF, Pillsbury HC (1982) Conservative treatment of infantile subglottic hemangioma with corticosteroids. Arch Otolaryngol 108(2):117–119PubMed
10.
Anonymous (1978) Treatment of complicated hemangiomas with adrenocorticosteroids when the integrity of important structures or life itself is threatened. J Dermatol Surg Oncol 4(11):854–858
11.
Hawkins DB, Crockett DM, Kahlstrom EJ, MacLaughlin EF (1984) Corticosteroid management of airway hemangiomas: long-term follow-up. Laryngoscope 94(1):633–637PubMed
12.
Mason BA, Dambra J, Grossman B et al (1982) Effective control of cisplatin-induced nausea using high-dose steroids and droperidol. Cancer 50:243–245
13.
Schell H (1972) Adrenal corticosteroid therapy in far advanced cancer. Geriatric 27:131–141
14.
Bruera E, Roca E, Cedaro L et al (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–754PubMed
15.
Bruera E, MacEachern T, Ripamonti C et al (1993) Subcutaneous morphine for dyspnea in cancer patients. Ann Intern Med 119:906–907PubMed
16.
Bruera E, Macmillan K, Pither J et al (1990) The effects of morphine on the dyspnea of terminal cancer patients. J Pain Sympt Manag 5:341–344CrossRef
17.
Cohen MH, Johnston Anderson A, Krasnow SH et al (1991) Continuous intravenous infusion of morphine for severe dyspnea. South Med J 84:229–234PubMed
18.
Del Fabbro E, Dalal S, Bruera E (2006) Symptom control in palliative care–Part III: dyspnea and delirium. J Palliat Med 9(2):422–436 ReviewPubMedCrossRef
19.
Hilton G, Frei J (1991) High-dose methylprednisolone in the treatment of spinal cord injuries. Heart Lung 20(6):675–680PubMed
20.
Muz J, Mathog RH, Nelson R, Jones LA Jr (2001) Aspiration in patients with head and neck cancer and tracheostomy. Am J Otolaryngol 10(4):282–286CrossRef
21.
Tanigawa N, Sawada S, Okuda Y et al (2000) Symptomatic improvement in dyspnea following tracheobronchial metallic stenting for malignant airway obstruction. Acta Radiol 41(5):694–701CrossRef
22.
Kim H (1998) Stenting therapy for stenosing airway disease. Respirology 4:221–228
Metadata
Title
High-dose corticosteroids for the management of dyspnea in patients with tumor obstruction of the upper airway
Authors
Ahmed Elsayem
Eduardo Bruera
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 12/2007
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0305-0

Other articles of this Issue 12/2007

Supportive Care in Cancer 12/2007 Go to the issue

Original Article

Dying at home or in an institution: perspectives of Dutch physicians and bereaved relatives

Erratum

A meta-analysis of exercise interventions among people treated for cancer

Original Article

Oxidative stress in lymphocytes, neutrophils, and serum of oral cavity cancer patients: modulatory array of l-glutamine

Original Article

Psychological distress of female cancer caregivers: effects of type of cancer and caregivers’ spirituality

Short Communication

Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia

Original Article

Endocrine symptom assessment in women with breast cancer: what a simple “yes” means
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits